Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
NCT05832229
This study is recruiting at 13 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cirrhosis
- Cirrhosis, Liver
- Cirrhosis Early
- Cirrhosis Due to Hepatitis B
- Cirrhosis Advanced
- Cirrhosis Infectious
- Cirrhosis Alcoholic
- Cirrhosis Due to Hepatitis C
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Last updated on ClinicalTrials.gov
- September 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 5
- University of California San Diego NAFLD Research Center · La Jolla, CA
- Keck Medical Center of USC · Los Angeles, CA
- LAC + USC Medical Center · Los Angeles, CA
- UCSF Medical Center · San Francisco, CA
- UCSF/Zuckerberg San Francisco General Hospital and Trauma Center · San Francisco, CA
Florida · 1
- University of Miami Health System · Miami, FL
Michigan · 1
- University of Michigan · Ann Arbor, MI
Minnesota · 1
- Mayo Clinic · Rochester, MN
New York · 2
- Columbia University Iriving School of Medicine · New York, NY
- New York Presbyterian/Weill Cornell · New York, NY
North Carolina · 1
- Duke Liver Center · Durham, NC
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Virginia · 1
- Virginia Commonwealth University · Richmond, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.